3 Undervalued Pharmaceuticals Stocks for Monday, March 11
Discover the top 3 undervalued Pharmaceuticals stocks for Monday, March 11 based on AAII’s Stock Grades.Eunice Kim
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Sunshine Biopharma, Inc. operates as a pharmaceutical company that engages in the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, dermatology, smoking cessation, cholelithiasis, anticonvulsant, urology, women's health, acid reflux, and anticonvulsant indications. Sunshine The company is based in Fort Lauderdale, Florida.
Commentary & Analysis
4 Undervalued Pharmaceuticals Stocks for Monday, February 05
Discover the top 4 undervalued Pharmaceuticals stocks for Monday, February 05 based on AAII’s Stock Grades.Grace Malone
6 Undervalued Pharmaceuticals Stocks for Wednesday, December 20
Discover the top 6 undervalued Pharmaceuticals stocks for Wednesday, December 20 based on AAII’s Stock Grades.Eunice Kim
7 Undervalued Pharmaceuticals Stocks for Friday, October 27
Discover the top 7 undervalued Pharmaceuticals stocks for Friday, October 27 based on AAII’s Stock Grades.Jack Gilleland
6 Undervalued Pharmaceuticals Stocks for Friday, September 08
Discover the top 6 undervalued Pharmaceuticals stocks for Friday, September 08 based on AAII’s Stock Grades.Grace Malone
Financial Summary
| Share Statistics | SBFM | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $4.5 | $286.3 | 3% |
|
| Shares Out (Mil) | 1.4 | 54.2 | 5% |
|
| Institutional Ownership | 95.2% | 92.8% | 67% |
|
| Float (Mil) | 2.1 | 39.7 | 5% |
|
| Beta | 1.31 | 0.94 | 77% |
|
| Avg Daily Volume (000s) | 1,328 | 534 | 75% |
|
| Price Change (52-week) |
(91.8%) | 58.7% | 3% |
|
| Growth | SBFM | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 225.1% | 13.6% | 100% |
|
| Net Income (5yr) | (16.5%) | (10.1%) | 24% |
|
| EPS (5yr) | na | 16.0% | na |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (15.6%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | SBFM | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $35 | $37 | 17% |
|
| Net Income (TTM) (Mil) | ($6) | ($43) | 33% |
|
| EPS (TTM) | ($8.195) | ($1.400) | 5% |
|
| Operating Cash Flow (TTM) (Mil) | ($5) | ($31) | 24% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $1 | $4 | 15% |
|
| Enterprise Value (Q1) (Mil) | ($9) | $160 | 2% |
|
| Valuation | SBFM | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.10 | 2.77 | 1% |
|
| P/E | na | 19.1 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | SBFM | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 30.3% | 64.2% | 35% |
|
| Net Margin | (16.5%) | (75.9%) | 18% |
|
| ROA | (17.8%) | (47.3%) | 21% |
|
| ROE | (21.9%) | (55.0%) | 23% |
|
| Liabilities to Assets | 18.1% | 29.6% | 12% |
|
| F-Score | 4 | 2 | 34% |
|
Sunshine Biopharma, Inc. did not pass any screens on 8/20/2026.
